...
首页> 外文期刊>Journal of land use science >A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products
【24h】

A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products

机译:通过LM-PCR全基因组扩增产物的低通测序进行单细胞基因组型拷贝分析的流线型工作流程

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Chromosomal instability and associated chromosomal aberrations are hallmarks of cancer and play a critical role in disease progression and development of resistance to drugs. Single-cell genome analysis has gained interest in latest years as a source of biomarkers for targeted-therapy selection and drug resistance, and several methods have been developed to amplify the genomic DNA and to produce libraries suitable for Whole Genome Sequencing (WGS). However, most protocols require several enzymatic and cleanup steps, thus increasing the complexity and length of protocols, while robustness and speed are key factors for clinical applications. To tackle this issue, we developed a single-tube, single-step, streamlined protocol, exploiting ligation mediated PCR (LM-PCR) Whole Genome Amplification (WGA) method, for low-pass genome sequencing with the Ion Torrent T platform and copy number alterations (CNAs) calling from single cells. The method was evaluated on single cells isolated from 6 aberrant cell lines of the NCI-H series. In addition, to demonstrate the feasibility of the workflow on clinical samples, we analyzed single circulating tumor cells (CTCs) and white blood cells (WBCs) isolated from the blood of patients affected by prostate cancer or lung adenocarcinoma. The results obtained show that the developed workflow generates data accurately representing whole genome absolute copy number profiles of single cell and allows alterations calling at resolutions down to 100 Kbp with as few as 200,000 reads. The presented data demonstrate the feasibility of the Ampli1 (TM) WGA-based lowpass workflow for detection of CNAs in single tumor cells which would be of particular interest for genome-driven targeted therapy selection and for monitoring of disease progression.
机译:染色体不稳定性和相关的染色体像差是癌症的标志,并在疾病进展和对药物抗性的发展中发挥关键作用。单细胞基因组分析对靶向治疗和耐药性的生物标志物来源产生了兴趣,并且已经开发了几种方法来扩增基因组DNA,并产生适合于全基因组测序(WGS)的文库。然而,大多数协议需要几种酶促和清理步骤,从而提高了协议的复杂性和长度,而鲁棒性和速度是临床应用的关键因素。为了解决这个问题,我们开发了一种单管,单步,流线型方案,利用连接介导的PCR(LM-PCR)全基因组扩增(WGA)方法,用于与离子粗糙T平台和副本进行低通基因组测序从单个单元格调用的数字变更(CNA)。在NCI-H系列6异常细胞系中分离的单细胞评估该方法。此外,为了证明工作流程对临床样本的可行性,我们分析了从受前列腺癌或肺腺癌影响的患者血液中分离的单循环肿瘤细胞(CTCS)和白细胞(WBC)。获得的结果表明,开发的工作流程可以准确地表示单个单元格的全基因组绝对拷贝数概况,并允许更改呼叫降至100 kBp的分辨率,只需20,000只读数。所提出的数据证明了基于AMPRI1(TM)WGA的低通工作流程的可行性,用于检测单一肿瘤细胞中的CNA,这对于基因组驱动的靶向治疗选择和监测疾病进展是特别令人兴趣的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号